MX389847B - Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. - Google Patents
Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.Info
- Publication number
- MX389847B MX389847B MX2019015311A MX2019015311A MX389847B MX 389847 B MX389847 B MX 389847B MX 2019015311 A MX2019015311 A MX 2019015311A MX 2019015311 A MX2019015311 A MX 2019015311A MX 389847 B MX389847 B MX 389847B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- acid esters
- cannabidiolic acid
- cannabidiolic
- symptoms
- Prior art date
Links
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical group OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522243P | 2017-06-20 | 2017-06-20 | |
| PCT/IL2018/050678 WO2018235079A1 (en) | 2017-06-20 | 2018-06-20 | Cannabidiolic acid esters compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019015311A MX2019015311A (es) | 2022-02-02 |
| MX389847B true MX389847B (es) | 2025-03-20 |
Family
ID=62875079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015311A MX389847B (es) | 2017-06-20 | 2018-06-20 | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11440870B2 (enExample) |
| EP (1) | EP3509638B1 (enExample) |
| JP (1) | JP2020524679A (enExample) |
| CN (1) | CN111032088A (enExample) |
| AU (1) | AU2018287018B2 (enExample) |
| BR (1) | BR112019026916A2 (enExample) |
| CA (1) | CA3067512A1 (enExample) |
| DK (1) | DK3509638T3 (enExample) |
| ES (1) | ES2909350T3 (enExample) |
| MX (1) | MX389847B (enExample) |
| PT (1) | PT3509638T (enExample) |
| WO (1) | WO2018235079A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| CA3067512A1 (en) | 2017-06-20 | 2018-12-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabidiolic acid esters compositions and uses thereof |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| AU2019412836A1 (en) * | 2018-12-25 | 2021-07-01 | Epm (Ip), Inc. | Cannabidiolic acid esters for cosmetic or edible compositions |
| US12403114B2 (en) * | 2019-03-12 | 2025-09-02 | Epm (Ip), Inc. | Cannabinoid acid ester compositions and uses thereof |
| EP4017485A1 (en) | 2019-08-22 | 2022-06-29 | EPM Group, Inc. | Cannabinoid acid ester compositions and uses thereof |
| WO2021137224A1 (en) * | 2020-01-01 | 2021-07-08 | Epm Group, Inc. | Cannabidiolic acid esters for treating muscular dystrophy |
| IL275108A (en) * | 2020-06-03 | 2022-01-01 | Epm Ip Inc | Abnormal acid cannabidiol (abn-cbd) derivatives and their uses |
| US20240000808A1 (en) * | 2020-11-16 | 2024-01-04 | Orcosa Inc. | Improved use of cannabinoids in the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022137144A1 (en) * | 2020-12-24 | 2022-06-30 | Buzzelet Development And Technologies Ltd. | Compositions comprising cannabinoid acid esters |
| US20230066947A1 (en) * | 2021-08-04 | 2023-03-02 | Max Hammond | Method for the augmentation of substance abuse therapies using cannabinoid formulations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2318468A1 (fr) * | 1975-07-17 | 1977-02-11 | Jaeger | Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres |
| US5342971A (en) | 1992-12-29 | 1994-08-30 | The Australian National University | Process for the preparation of dibenzo[b,d]pyrans |
| ES2224658T3 (es) | 1998-05-04 | 2005-03-01 | The University Of Connecticut | Nuevos canabinoides selectivos hacia el receptor cb2. |
| IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| JP2008502690A (ja) | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン， | リン脂質組成物ならびにその調製方法および使用方法 |
| AU2006297300B2 (en) * | 2005-09-29 | 2012-05-10 | Albany Molecular Research, Inc. | Process for production of delta-9-tetrahydrocannabinol |
| CN101384012B (zh) * | 2008-10-22 | 2012-05-23 | 华为终端有限公司 | 系统端和终端的交互媒体文档更新方法及装置 |
| DE102009019322A1 (de) | 2009-04-30 | 2010-11-11 | The Health Concept Gmbh | Verfahren zur Herstellung von Synthetischen Cannabinoiden |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| GB2494461A (en) | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
| GB2515312A (en) | 2013-06-19 | 2014-12-24 | Gw Pharma Ltd | The use of phytocannabinoids in the treatment of ovarian carcinoma |
| EP2842933B1 (de) | 2013-09-03 | 2015-07-29 | Symrise AG | Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung |
| CN106232570B (zh) * | 2014-04-16 | 2018-08-07 | 维瓦赛尔生物技术西班牙有限公司 | 新的大麻二酚醌衍生物 |
| GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| GB2531283A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiols in the treatment of degenerative skeletal muscle diseases |
| EP3061450A1 (de) | 2015-02-26 | 2016-08-31 | Symrise AG | Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| CN106810426B (zh) * | 2016-12-29 | 2020-05-08 | 暨明医药科技（苏州）有限公司 | 一种大麻二酚的合成方法 |
| CA3067512A1 (en) | 2017-06-20 | 2018-12-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cannabidiolic acid esters compositions and uses thereof |
| WO2019234728A1 (en) | 2018-06-04 | 2019-12-12 | Al&Am Pharmachem Ltd. | Cannabinolic acid derivatives and uses thereof |
-
2018
- 2018-06-20 CA CA3067512A patent/CA3067512A1/en active Pending
- 2018-06-20 ES ES18739958T patent/ES2909350T3/es active Active
- 2018-06-20 JP JP2019570108A patent/JP2020524679A/ja active Pending
- 2018-06-20 CN CN201880041597.0A patent/CN111032088A/zh active Pending
- 2018-06-20 PT PT187399589T patent/PT3509638T/pt unknown
- 2018-06-20 MX MX2019015311A patent/MX389847B/es unknown
- 2018-06-20 WO PCT/IL2018/050678 patent/WO2018235079A1/en not_active Ceased
- 2018-06-20 AU AU2018287018A patent/AU2018287018B2/en active Active
- 2018-06-20 DK DK18739958.9T patent/DK3509638T3/da active
- 2018-06-20 EP EP18739958.9A patent/EP3509638B1/en active Active
- 2018-06-20 BR BR112019026916-9A patent/BR112019026916A2/pt not_active Application Discontinuation
- 2018-06-20 US US16/343,050 patent/US11440870B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2909350T3 (es) | 2022-05-06 |
| BR112019026916A2 (pt) | 2020-06-30 |
| EP3509638B1 (en) | 2022-01-12 |
| JP2020524679A (ja) | 2020-08-20 |
| EP3509638A1 (en) | 2019-07-17 |
| PT3509638T (pt) | 2022-03-02 |
| CN111032088A (zh) | 2020-04-17 |
| DK3509638T3 (da) | 2022-04-11 |
| MX2019015311A (es) | 2022-02-02 |
| US11440870B2 (en) | 2022-09-13 |
| AU2018287018B2 (en) | 2022-04-28 |
| WO2018235079A1 (en) | 2018-12-27 |
| US20200115317A1 (en) | 2020-04-16 |
| AU2018287018A1 (en) | 2020-01-30 |
| CA3067512A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389847B (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| CR20190063A (es) | 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2 | |
| CL2017002123A1 (es) | Heterociclos biciclicos como inhibidores de fgnr | |
| CO2017013443A2 (es) | Composiciones que comprenden cepas bacterianas del género blautia | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| MX385845B (es) | Usos y composiciones de la flagelina | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| AR106768A1 (es) | Composiciones que comprenden cepas bacterianas | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| UY34617A (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas | |
| DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| CL2017001301A1 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| UY36171A (es) | Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa | |
| MX2021000773A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? |